{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bipolar-disorder/prescribing-information/valproate/","result":{"pageContext":{"chapter":{"id":"1933741e-2f27-57bf-92f1-5d769518344f","slug":"valproate","fullItemName":"Valproate","depth":2,"htmlHeader":"<!-- begin field ba5c6f32-4c1c-4e8d-9f17-eb2c7a10e3ac --><h2>Valproate</h2><!-- end field ba5c6f32-4c1c-4e8d-9f17-eb2c7a10e3ac -->","summary":"","htmlStringContent":"<!-- begin item 04cd4573-fa8e-49ca-b1f6-525329f907ca --><!-- end item 04cd4573-fa8e-49ca-b1f6-525329f907ca -->","topic":{"id":"ac644ce3-3932-5e1f-8676-4ebcfb5f240d","topicId":"87d084eb-bc7f-45b7-9384-f490e6417d9d","topicName":"Bipolar disorder","slug":"bipolar-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"3ed6a7a1-589c-57a9-89fd-e61f76a4c198","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96f8d073-2e2b-55bd-9f94-a0cf336756a7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5a048129-7c1e-5fc5-8a8a-3e91b2be7e18","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d98476-085c-58c4-b646-093d1564a66c","slug":"changes","fullItemName":"Changes"},{"id":"e8e86070-9a3a-5b97-8a3b-d76771dd7e92","slug":"update","fullItemName":"Update"}]},{"id":"308f8462-ca53-5dee-9a6a-463a88283762","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e56ddcf1-8ade-5c55-ada8-cd9307fa9d45","slug":"goals","fullItemName":"Goals"},{"id":"c9a278dc-a960-595c-90fa-702a979fe434","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6c858f7e-b8a9-5125-9b30-d15ff9489c89","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"caccf5a3-718b-556f-a3d7-e412c84fffec","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1d1a32a6-8f9b-54ef-8db8-35685fd71f28","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"31f4b1ea-76e5-5273-821f-7ba3fd77ac0e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b529213a-3211-53f9-b870-f03b9a1d30c9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"53fd9729-258a-5bc1-ac8d-c7c2ebdfd92e","slug":"definition","fullItemName":"Definition"},{"id":"0dc41761-cd41-54cc-8277-c96320874497","slug":"causes","fullItemName":"Causes"},{"id":"2c7c3452-f7d6-5a4d-ac13-72ecad737a44","slug":"incidence-prevalence","fullItemName":"Incidence and prevalence"},{"id":"7a53a39d-073b-5a29-b48d-a0ff3049049e","slug":"complications","fullItemName":"Complications"},{"id":"ae1afd6c-efdb-5d1f-82a9-ee9a07103bde","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"45d991bb-5121-511b-a201-826c8297a59d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff54cf2c-7ebb-58b5-a77c-a285db95f263","slug":"suspecting-bipolar-disorder","fullItemName":"Suspecting bipolar disorder"},{"id":"a5cf6d30-ba09-58fa-b2a2-78490ef3dfe6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0c45d8c8-9038-5e75-9637-34b9b70a708f","fullItemName":"Management","slug":"management","subChapters":[{"id":"08d1a671-233b-56fe-9343-455ae9d9457c","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"3168933b-1d1b-56e0-82d5-13b7a4175ed1","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"7fd5675a-5f41-5662-86a1-dcd7103d1e7b","slug":"routine-bipolar-disorder-review","fullItemName":"Scenario: Routine bipolar disorder review"},{"id":"7cd1d695-071f-5e74-945f-e61927a44a85","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"7be9863d-b620-5545-b0ca-d2a5ea14af95","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d0da96ab-51ae-530a-ac52-76b445fb10a5","slug":"ssris","fullItemName":"SSRIs"},{"id":"7ccedc62-ec67-54d4-a721-f520c7573553","slug":"antipsychotics","fullItemName":"Antipsychotics"},{"id":"587e9545-d869-5933-b101-2407ad59bc52","slug":"lamotrigine","fullItemName":"Lamotrigine"},{"id":"f1925178-1888-5bf8-8868-92a526afff0f","slug":"lithium","fullItemName":"Lithium"},{"id":"1933741e-2f27-57bf-92f1-5d769518344f","slug":"valproate","fullItemName":"Valproate"}]},{"id":"1913037b-d494-5a34-be7c-baf4cb96acd4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"88a92260-20b8-51eb-8b46-3a2409ddf63b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"438d8ad5-e57e-58be-8902-0a3160dc221d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4449bc7-d64d-5a1c-a07a-b9a548cc3172","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"be352ccd-5a94-556d-b076-f450b54edbfb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"999ad09a-2f9f-562d-9583-938295801e7f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a2be53e8-c67a-5bbd-a684-a352c46d9902","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c4e156df-5e61-50f0-bcf6-60433f5a4e37","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7be9863d-b620-5545-b0ca-d2a5ea14af95","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"24d00802-490f-57e9-90ee-35b4300f6533","slug":"prescribing","fullItemName":"Prescribing","depth":3,"htmlHeader":"<!-- begin field b9e86924-ab19-468f-84ce-bda915d6d502 --><h3>How should I prescribe valproate?</h3><!-- end field b9e86924-ab19-468f-84ce-bda915d6d502 -->","summary":"","htmlStringContent":"<!-- begin item 6450d7df-d7e2-45e7-bb92-88afa82bea8d --><!-- begin field 083d00e7-f343-4cae-9d1a-d99a5aed81d4 --><ul><li><strong>Valproate is available in the UK in two forms:</strong><ul><li>Semisodium valproate (Depakote<sup>®</sup>) is licensed for the treatment of acute mania (but is not licensed for use in children).</li><li>Sodium valproate (Epilim<sup>®</sup>) and valproic acid (Convulex<sup>®</sup>) are both <em>unlicensed </em>for the treatment of bipolar disorder.</li></ul></li><li><strong>Both semisodium and sodium valproate are metabolized to valproic acid, which is responsible for their pharmacological activity.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 083d00e7-f343-4cae-9d1a-d99a5aed81d4 --><!-- end item 6450d7df-d7e2-45e7-bb92-88afa82bea8d -->","subChapters":[]},{"id":"0ba2b246-5b9c-514e-8264-2a600037c96b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a57a88fd-9ab1-46ac-86d1-7b2fde0ddb9c --><h3>What are the contraindications and cautions?</h3><!-- end field a57a88fd-9ab1-46ac-86d1-7b2fde0ddb9c -->","summary":"","htmlStringContent":"<!-- begin item ae5e8fb4-b61d-40d2-abda-e69dbebb1e55 --><!-- begin field dd11cbf1-98e0-4805-a5e1-5325ff0d13ab --><ul><li><strong>Do not prescribe valproate to people with:</strong><ul><li>Active liver disease.</li><li>Personal or family history of severe, drug-related, hepatic dysfunction.</li><li>Acute porphyria.</li><li>Mitochondrial disorders caused by mutations in the nuclear gene encoding the mitochondrial enzyme polymerase γ (POLG), for example Alpers-Huttenlocher Syndrome.</li></ul></li><li><strong>The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends that valproate should <em>not</em> be prescribed to female children, female adolescents, women of childbearing potential, or pregnant women to treat bipolar disorder unless the illness is very severe and there is no effective alternative option. Females of childbearing potential taking valproate should be enrolled in a pregnancy prevention plan. Valproate is a teratogen and can cause physical birth defects and developmental disorders in children exposed <em>in utero</em>.</strong><ul><li>The MHRA has produced a <a data-hyperlink-id=\"caa4f6f1-0ec7-4ab1-8a55-a98c00d0328a\" href=\"https://www.gov.uk/government/publications/toolkit-on-the-risks-of-valproate-medicines-in-female-patients\">toolkit</a> to help healthcare professionals advise women about the risks of taking valproate during pregnancy. </li><li>The available communication tools to support discussions with women on the risks of taking valproate in pregnancy include a healthcare professional <a data-hyperlink-id=\"420b5541-f087-4a52-8a92-a98c00d032a3\" href=\"http://www.medicines.org.uk/emc/RMM.420.pdf\">booklet</a>, a <a data-hyperlink-id=\"ac001fa1-7684-4a52-bee2-a98c00d032e7\" href=\"http://www.medicines.org.uk/emc/RMM.423.pdf\">consultation checklist</a>, as well as a <a data-hyperlink-id=\"6c9fe68f-c653-40b6-a7a5-a98c00d0332b\" href=\"http://www.medicines.org.uk/emc/RMM.421.pdf\">guide</a> and <a data-hyperlink-id=\"7ff115c0-f998-4e5d-b48a-a98c00d03384\" href=\"http://www.medicines.org.uk/emc/RMM.422.pdf\">card</a> to give to women who are taking valproate. A freely available patient information leaflet on <a data-hyperlink-id=\"7ca1c1e2-4275-4c95-85a0-aa9101006d7f\" href=\"http://www.medicinesinpregnancy.org/Medicine--pregnancy/Valproic-acid/\">use of valproate in pregnancy</a> is available from the UK teratology information service.</li></ul></li><li><strong>NICE recommends that if women or young girls of childbearing potential are already taking valproate they should be advised to gradually stop the medicine because of the risk of fetal malformations and adverse neurodevelopmental outcomes after any exposure in pregnancy </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">NICE, 2020a</a>]. </li><li><strong>Prescribe valproate with caution to people with systemic lupus erythematosus.</strong></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">MHRA, 2019</a>]</p><!-- end field dd11cbf1-98e0-4805-a5e1-5325ff0d13ab --><!-- end item ae5e8fb4-b61d-40d2-abda-e69dbebb1e55 -->","subChapters":[]},{"id":"733fdb46-8e12-53b5-ad36-c2966c16b244","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 4a543fc2-52c2-4ebe-82a1-a80af3fc31dc --><h3>What are the adverse effects of valproate?</h3><!-- end field 4a543fc2-52c2-4ebe-82a1-a80af3fc31dc -->","summary":"","htmlStringContent":"<!-- begin item 462fe10e-c675-4054-964c-247baba82c1d --><!-- begin field c909a02a-7e2a-4023-a80f-f34a63489a56 --><ul><li><strong>Adverse effects of valproate include:</strong><ul><li>Gastric irritation, and hyperammonaemia both of which can lead to intense nausea.</li><li>Lethargy and confusion. This can occur with starting doses of more than 750 mg a day.</li><li>Weight gain.</li><li>Hair loss, with curly regrowth.</li><li>Peripheral oedema.</li><li>Very rarely, fulminant hepatic failure.</li><li>Hyperandrogenism in women. This has been linked to the development of polycystic ovaries.</li><li>Thrombocytopenia, leucopenia, red cell hypoplasia, and pancreatitis.</li><li>There is a small risk of suicidal thoughts and behaviour, which may be seen as early as one week after starting treatment. People taking valproate and healthcare professionals should be alert to any mood changes, distressing thoughts, or feelings about suicide or harming themselves at any point during treatment. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Taylor et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field c909a02a-7e2a-4023-a80f-f34a63489a56 --><!-- end item 462fe10e-c675-4054-964c-247baba82c1d -->","subChapters":[]},{"id":"31dde513-d1c3-5106-961b-57b962492025","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 8989d5d5-995d-4d49-809d-da5cbded6922 --><h3>What are the key drug interactions of valproate?</h3><!-- end field 8989d5d5-995d-4d49-809d-da5cbded6922 -->","summary":"","htmlStringContent":"<!-- begin item 0f8c9ecc-531c-4b3b-9442-d9cae86ba163 --><!-- begin field f70819ec-9696-478e-b3de-bc5614f32875 --><ul><li>Valproate is highly protein-bound (up to 94%), and other drugs that are also highly protein bound (e.g. aspirin) may displace valproate from albumin and precipitate toxicity.</li><li>Other less strongly protein-bound drugs (for example warfarin) can be displaced by valproate; this may lead to higher free levels and increased therapeutic effect or toxicity of the concomitant drug.</li><li>Valproate is metabolized by the liver, so drugs that inhibit cytochrome P450 enzymes (for example erythromycin, fluoxetine, and cimetidine) can increase valproate levels.</li><li>Valproate can increase the plasma levels of some drugs, possibly by inhibition of their metabolism (for example tricyclic antidepressants, particularly clomipramine).</li><li>Nimodipine — the levels of this drug can be increased when taken with valproate. A dose reduction of nimodipine should be made is a person suffers hypotension.</li><li>Lamotrigine — valproate increases the exposure to lamotrigine. Manufacturer advises adjust lamotrigine dose and monitor for rash.</li><li>Carbapenem antibiotics (such as panipenem, imipenem and meropenem) —<strong><em> </em></strong>decreases in blood levels of valproic acid have been reported during co-administration with carbapenem antibiotics leading to a 60% – 100% decrease in valproic acid levels within two days.<strong> </strong>Co-administration should therefore be avoided. If treatment with these antibiotics cannot be avoided close monitoring of valproic acid blood levels should be performed.</li><li>Quetiapine — co-administration may increase the risk of neutropenia/leucopenia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Taylor et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field f70819ec-9696-478e-b3de-bc5614f32875 --><!-- end item 0f8c9ecc-531c-4b3b-9442-d9cae86ba163 -->","subChapters":[]},{"id":"effdc365-3981-59eb-9813-86c491f74bab","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 8e113971-a50d-4843-abed-e964cc823263 --><h3>How should I monitor someone taking valproate?</h3><!-- end field 8e113971-a50d-4843-abed-e964cc823263 -->","summary":"","htmlStringContent":"<!-- begin item a6a130a4-611a-4600-8988-1e1f3233af3d --><!-- begin field 4077dc43-30f5-434d-8f39-2bd7503fcc54 --><ul><li>Before starting treatment, a full blood count, baseline liver function tests (LFTs), and body weight or body mass index (BMI) are usually measured.</li><li>Ensure that LFTs (including prothrombin time), BMI, and a full blood count are measured 6 months after treatment has been initiated, and every 12 months thereafter.</li><li>Valproate levels are not routinely measured unless there is evidence of ineffectiveness, poor compliance, or toxicity is suspected.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">NICE, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 4077dc43-30f5-434d-8f39-2bd7503fcc54 --><!-- end item a6a130a4-611a-4600-8988-1e1f3233af3d -->","subChapters":[]},{"id":"27fd579c-5e96-5e81-8a27-7e198745c45f","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 42c87a06-4d04-42e4-8556-67622442c683 --><h3>What advice should I give to someone taking valproate?</h3><!-- end field 42c87a06-4d04-42e4-8556-67622442c683 -->","summary":"","htmlStringContent":"<!-- begin item 4e47e3a0-59e6-48bd-8f43-5e387862c429 --><!-- begin field 527cef81-557c-4228-a11d-42fb7bde8878 --><ul><li><strong>Advise the person and their carers how to recognize the signs and symptoms of:</strong><ul><li><strong>Blood disorders </strong>(for example any unexplained bleeding, bruising, purpura, sore throat, fever, or malaise that occurs during treatment).</li><li><strong>Liver disorders </strong>(for example sudden onset of weakness, malaise, anorexia, lethargy, oedema, and drowsiness [which are sometimes associated with repeated vomiting and abdominal pain], and jaundice).</li><li><strong>Pancreatitis </strong>(for example abdominal pain, nausea, and vomiting).</li></ul></li><li><strong>Inform them that they should seek immediate medical help if these develop.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 527cef81-557c-4228-a11d-42fb7bde8878 --><!-- end item 4e47e3a0-59e6-48bd-8f43-5e387862c429 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}